Loading
Surgery that removes as much tumour as possible when it cannot all be removed cleanly; leaving nothing visible behind is what matters.
Central to ovarian cancer, where survival tracks the residual disease after surgery: complete cytoreduction (no visible tumour) is the goal. Primary debulking is done first if feasible; otherwise three cycles of carboplatin-paclitaxel are followed by interval debulking (EORTC 55971, CHORUS). Secondary cytoreduction at platinum-sensitive relapse helps selected patients (DESKTOP III) but not unselected ones (GOG-0213). Cytoreductive surgery plus HIPEC is used for peritoneal disease from appendix, colorectal and ovarian cancers, and cytoreductive nephrectomy in kidney cancer.
Showing the technology this term belongs to: HIPEC / PIPAC (intraperitoneal chemotherapy).
Shares HIPEC (hyperthermic intraperitoneal chemotherapy), Netherlands Cancer Institute HIPEC trial, PRODIGE 7, Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei.
Shares Netherlands Cancer Institute HIPEC trial, PRODIGE 7, HIPEC / PIPAC (intraperitoneal chemotherapy), Colorectal cancer.
Shares Netherlands Cancer Institute HIPEC trial, PRODIGE 7, HIPEC / PIPAC (intraperitoneal chemotherapy), Colorectal cancer.
Shares HIPEC (hyperthermic intraperitoneal chemotherapy), Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei, HIPEC / PIPAC (intraperitoneal chemotherapy).
Shares HIPEC / PIPAC (intraperitoneal chemotherapy), Ovarian cancer, Colorectal cancer.
Shares HIPEC / PIPAC (intraperitoneal chemotherapy), Ovarian cancer, Colorectal cancer.
Shares Nephrectomy, Renal cell carcinoma.
Shares Nephrectomy, Neoadjuvant / adjuvant / perioperative, Renal cell carcinoma.